Who Paid My Doc
Laxmaiah Manchikanti
Interventional Pain Medicine Paducah, KY Medical Doctor
NPI 1730178799 CMS profile 782748
2831 Lone Oak Rd, Paducah, KY 42003
General payments
$695
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$50
Through program year 2025, Laxmaiah Manchikanti of Paducah, KY is reported in the CMS Open Payments database as having received $695 across 18 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $50 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 20th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $74 | 4 | |
| 2024 | General | $114 | 2 | |
| 2023 | General | $349 | 9 | |
| 2022 | General | $14 | 1 | |
| 2019 | General | $144 | 2 |
Beside peers
- Laxmaiah Manchikanti
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Laxmaiah Manchikanti were reported at $74. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Laxmaiah Manchikanti | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $144 | $684 | $216–$2,079 | $163 |
| 2020 | $0 | $382 | $122–$1,109 | $114 |
| 2021 | $0 | $552 | $167–$1,554 | $132 |
| 2022 | $14 | $605 | $187–$1,924 | $149 |
| 2023 | $349 | $671 | $195–$1,915 | $160 |
| 2024 | $114 | $684 | $206–$1,837 | $164 |
| 2025 | $74 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 44 drugsPart D claims
15,794
Drug cost
$407,089
Branded share of claims
54.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 3,657 | $93,615 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 4,216 | $88,340 | |
| Movantik Naloxegol Oxalate | Brand | 119 | $47,620 | |
| Gabapentin | Generic | 2,586 | $22,507 | |
| Oxycontin Oxycodone Hcl | Brand | 27 | $19,793 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 129 | $19,281 | |
| Nucynta Tapentadol Hcl | Brand | 20 | $18,949 | |
| Oxycodone Hcl | Generic | 701 | $13,493 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 393 | $12,593 | |
| Lyrica Pregabalin | Brand | 12 | $12,415 |
The 10 drugs with the highest cost, of 44 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 43 billing codesPaid by Medicare
$305,112
Medicare patients
710
Services billed
3,913
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 38% | |
| COPD | 37% | |
| Diabetes | 36% | |
| Chronic kidney disease | 26% | |
| Ischemic heart disease | 25% | |
| Heart failure | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Kentucky
Robert Klickovich
Interventional Pain Medicine · Florence, KY
Hammad Malik
Interventional Pain Medicine · Richmond, KY
Michael Fletcher
Interventional Pain Medicine · Florence, KY
Vishal Bansal
Interventional Pain Medicine · Madisonville, KY
Anand Modadugu
Interventional Pain Medicine · Lexington, KY
Zachary Klinger
Interventional Pain Medicine · Corbin, KY
Related records
Interventional Pain Medicine in Kentucky
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Kentucky
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.